Yingqi Hua
Shanghai Jiao Tong University(CN)Capital Medical University(CN)Chinese Academy of Sciences(CN)Changchun Institute of Optics, Fine Mechanics and Physics(CN)Shunyi Hospital of Beijing Traditional Chinese Medicine Hospital(CN)Shanghai Cancer Institute(CN)Beijing Anzhen Hospital(CN)Wanhua Chemical (China)(CN)Shanghai First People's Hospital(CN)University of Chinese Academy of Sciences(CN)Chongqing University of Technology(CN)University of Pennsylvania(US)Nanjing Medical University(CN)
Publications by Year
Research Areas
Sarcoma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Cancer, Hypoxia, and Metabolism, Radiopharmaceutical Chemistry and Applications, Cancer-related molecular mechanisms research
Most-Cited Works
- → Immunogenic cell death in cancer therapy: Present and emerging inducers(2019)706 cited
- → Erianin induces G2/M-phase arrest, apoptosis, and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells in vitro and in vivo(2016)226 cited
- → The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis(2013)176 cited
- → Arsenic sulfide induces apoptosis and autophagy through the activation of ROS/JNK and suppression of Akt/mTOR signaling pathways in osteosarcoma(2017)152 cited
- → Sarcoma-Targeting Peptide-Decorated Polypeptide Nanogel Intracellularly Delivers Shikonin for Upregulated Osteosarcoma Necroptosis and Diminished Pulmonary Metastasis(2018)149 cited
- → Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma(2019)